It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...
Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...
Pharma companies are growing keen on integrating AI into their processes. Recursion Pharmaceuticals could help collaborators reduce their costs. At the same time, it could also help pharma giants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results